ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,948Medicare Part D Prescriptions Filled, Including Refills

Rank: 7 out of 302

$403K Total Retail Price of All Prescriptions

Rank: 30 out of 302

430 Patients Receiving at Least One Drug in Part D
57%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 430 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

13% of this provider’s 430 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 4,376 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $100 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LISINOPRIL 577 342 1 1
METFORMIN HCL 263 146 2 13
PRAVASTATIN SODIUM 224 97 3 17
AMLODIPINE BESYLATE 193 134 4 2
OMEPRAZOLE 190 94 5 7
SIMVASTATIN 180 101 6 3
LEVOTHYROXINE SODIUM 170 106 7 9
METOPROLOL TARTRATE 168 113 8 5
ATORVASTATIN CALCIUM 147 106 9 10
ATENOLOL 137 119 10 20
CRESTOR 129 64 11 34
HYDROCHLOROTHIAZIDE 116 72 12 12
GLYBURIDE-METFORMIN HCL 114 69 R 13 145
FUROSEMIDE 112 73 14 4
TRAZODONE HCL 110 41 15 36
LISINOPRIL-HYDROCHLOROTHIAZIDE 110 77 15 53
PROAIR HFA 102 22 17 81
METOPROLOL SUCCINATE 101 62 18 6
RANITIDINE HCL 98 35 19 33
AMOXICILLIN 93 59 20 181
WARFARIN SODIUM 91 36 21 8
LOVASTATIN 82 55 22 63
TRAMADOL HCL 81 27 23 16
VENTOLIN HFA 77 35 24 127
SERTRALINE HCL 77 60 24 43
OXYCODONE-ACETAMINOPHEN 75 41 S2 26 22
IBUPROFEN 70 16 27 91
FLUOXETINE HCL 70 39 27 105
ESCITALOPRAM OXALATE 70 24 27 116
GLYBURIDE 69 24 R 30 111
AZITHROMYCIN 66 30 31 79
ZOLPIDEM TARTRATE 66 36 31 28
PROPRANOLOL HCL 65 21 33 151
POTASSIUM CHLORIDE 64 46 34 55
HYDROCODONE-ACETAMINOPHEN 64 37 S3 34 15
SPIRIVA 61 38 36 112
DICLOFENAC SODIUM 61 40 36 146
LYRICA 60 15 38 78
CITALOPRAM HBR 60 40 38 30
TAMSULOSIN HCL 53 25 40 41
ADVAIR DISKUS 53 42 40 61
NAPROXEN 52 38 42 120
CLOPIDOGREL 51 42 43 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 2, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.